Intercept Pharma Danmark ApS: Financial statements 2017
CVR: 37104469
Source: annual report 2017, Danish Business Authority
01/01/2017 – 31/12/2017
Intercept Pharma Danmark ApS (CVR 37104469) has filed annual accounts for 2017. In 2017, the company reported a gross profit of DKK -9,176,767 and a net result of DKK -25,789,009. Equity in the 2017 report amounted to DKK -31,718,678. The company had 5 employees in the financial year.
- Gross Profit
- DKK -9,176,767
- Profit/Loss
- DKK -25,789,009
- Equity
- DKK -31,718,678
- Total Assets
- DKK 6,931,361
- Employees
- 5
Keep an eye on Intercept Pharma Danmark ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2017
As of December 31, 2017, Seokho Bryan Yoon has stepped down as director of Intercept Pharma Danmark ApS.
As of December 31, 2017, Gülizar Aybasti Skjoldager has stepped down as director of Intercept Pharma Danmark ApS.
Intercept Pharma Danmark ApS has published its interim report for the period September 23, 2015 – December 31, 2016.
As of May 30, 2017, Sandipkumar Shantilal Kapadia is registered as director of Intercept Pharma Danmark ApS.
As of May 30, 2017, Barbara Duncan has stepped down as director of Intercept Pharma Danmark ApS.
About Intercept Pharma Danmark ApS
Intercept Pharma Danmark ApS was a Danish company of the type Anpartsselskab based in København Ø, founded in 2015 and dissolved in 2020. The company was registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company has 1 employee (2018). In 2019, the company reported a gross profit of DKK 2,803,867 and a net result of DKK -27,225 compared with DKK -7,148,070 the year before. Equity in the 2019 report amounted to DKK -38,893,973.